Androgens modulate male-derived endothelial cell homeostasis using androgen receptor-dependent and receptor-independent mechanisms

Angiogenesis

Volumn 20, Issue 1, 2017, Pages 25-38

  Torres Estay, Verónica ^a   Carreño, Daniela V ^a   Fuenzalida, Patricia ^a   Watts, Anica ^b   San Francisco, Ignacio F ^a   Montecinos, Viviana P ^a   Sotomayor, Paula C ^c   Ebos, John ^b   Smith, Gary J ^b   Godoy, Alejandro S ^a,b  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSIDAD ANDRÉS BELLO   (Chile)

Author keywords

Androgen receptor; Androgens; Angiogenesis; Endothelial cells

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; CYCLOPHILIN; ANDROSTANE DERIVATIVE; ANDROSTERONE; MESSENGER RNA;

ARTICLE; BIOLOGICAL ACTIVITY; CELL COUNTING; CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; FETUS; HOMEOSTASIS; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; METABOLITE; MTT ASSAY; PLEIOTROPY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; SEX DIFFERENCE; TISSUE MICROARRAY; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR BIOLOGY; ANGIOGENESIS; ANTIBODY SPECIFICITY; BIOLOGICAL MODEL; CHEMISTRY; DRUG EFFECTS; GENETICS; METABOLISM;

ANDROGENS; ANDROSTANOLS; ANDROSTERONE; CELL PROLIFERATION; CELL SURVIVAL; DIHYDROTESTOSTERONE; FEMALE; HOMEOSTASIS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PHYSIOLOGIC; ORGAN SPECIFICITY; RECEPTORS, ANDROGEN; RNA, MESSENGER;

EID: 84988730422     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-016-9525-6     Document Type: Article

References (51)

1. Laudet V, Hanni C, Coll J, Catzeflis F, Stehelin D (1992) Evolution of the nuclear receptor gene superfamily. EMBO J 11(3):1003–1013
2. Blauer M, Vaalasti A, Pauli SL, Ylikomi T, Joensuu T, Tuohimaa P (1991) Location of androgen receptor in human skin. J Invest Dermatol 97(2):264–268
3. Laine M, Blauer M, Ylikomi T, Tuohimaa P, Aitasalo K, Happonen RP, Tenovuo J (1993) Immunohistochemical demonstration of androgen receptors in human salivary glands. Arch Oral Biol 38(4):299–302
4. Abu EO, Horner A, Kusec V, Triffitt JT, Compston JE (1997) The localization of androgen receptors in human bone. J Clin Endocrinol Metab 82(10):3493–3497
5. Mantalaris A, Panoskaltsis N, Sakai Y, Bourne P, Chang C, Messing EM, Wu JH (2001) Localization of androgen receptor expression in human bone marrow. J Pathol 193(3):361–366
6. Schultheiss D, Badalyan R, Pilatz A, Gabouev AI, Schlote N, Wefer J, von Wasielewski R, Mertsching H, Sohn M, Stief CG, Jonas U (2003) Androgen and estrogen receptors in the human corpus cavernosum penis: immunohistochemical and cell culture results. World J Urol 21(5):320–324
7. Sinha-Hikim I, Taylor WE, Gonzalez-Cadavid NF, Zheng W, Bhasin S (2004) Androgen receptor in human skeletal muscle and cultured muscle satellite cells: up-regulation by androgen treatment. J Clin Endocrinol Metab 89(10):5245–5255
8. Godoy A, Watts A, Sotomayor P, Montecinos VP, Huss WJ, Onate SA, Smith GJ (2008) Androgen receptor is causally involved in the homeostasis of the human prostate endothelial cell. Endocrinology 149(6):2959–2969. doi:10.1210/en.2007-1078
9. Godoy AS, Chung I, Montecinos VP, Buttyan R, Johnson CS, Smith GJ (2013) Role of androgen and vitamin D receptors in endothelial cells from benign and malignant human prostate. Am J Physiol Endocrinol Metab 304(11):E1131–E1139. doi:10.1152/ajpendo.00602.2012
10. Torres-Estay V, Carreno DV, San Francisco IF, Sotomayor P, Godoy AS, Smith GJ (2015) Androgen receptor in human endothelial cells. J Endocrinol 224(3):R131–R137. doi:10.1530/JOE-14-0611
11. Yoshida S, Ikeda Y, Aihara K (2016) Roles of the androgen–androgen receptor system in vascular angiogenesis. J Atheroscler Thromb 23(3):257–265. doi:10.5551/jat.31047
12. Buttyan R, Shabsigh A, Perlman H, Colombel M (1999) Regulation of apoptosis in the prostate gland by androgenic steroids. Trends Endocrinol Metab 10(2):47–54
13. Cheng L, Zhang S, Sweeney CJ, Kao C, Gardner TA, Eble JN (2004) Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model. Anticancer Res 24(4):2135–2140
14. Godoy A, Montecinos VP, Gray DR, Sotomayor P, Yau JM, Vethanayagam RR, Singh S, Mohler JL, Smith GJ (2011) Androgen deprivation induces rapid involution and recovery of human prostate vasculature. Am J Physiol Endocrinol Metab 300(2):E263–E275. doi:10.1152/ajpendo.00210.2010
15. Hougaku H, Fleg JL, Najjar SS, Lakatta EG, Harman SM, Blackman MR, Metter EJ (2006) Relationship between androgenic hormones and arterial stiffness, based on longitudinal hormone measurements. Am J Physiol Endocrinol Metab 290(2):E234–E242
16. Alexandersen P, Haarbo J, Byrjalsen I, Lawaetz H, Christiansen C (1999) Natural androgens inhibit male atherosclerosis: a study in castrated, cholesterol-fed rabbits. Circ Res 84(7):813–819
17. Dockery F, Bulpitt CJ, Donaldson M, Fernandez S, Rajkumar C (2003) The relationship between androgens and arterial stiffness in older men. J Am Geriatr Soc 51(11):1627–1632
18. Malkin CJ, Pugh PJ, Jones RD, Jones TH, Channer KS (2003) Testosterone as a protective factor against atherosclerosis–immunomodulation and influence upon plaque development and stability. J Endocrinol 178(3):373–380
19. Kang SM, Jang Y, Kim JY, Chung N, Cho SY, Chae JS, Lee JH (2002) Effect of oral administration of testosterone on brachial arterial vasoreactivity in men with coronary artery disease. Am J Cardiol 89(7):862–864
20. Kalin MF, Zumoff B (1990) Sex hormones and coronary disease: a review of the clinical studies. Steroids 55(8):330–352
21. Montalcini T, Gorgone G, Gazzaruso C, Sesti G, Perticone F, Pujia A (2007) Endogenous testosterone and endothelial function in postmenopausal women. Coron Artery Dis 18(1):9–13
22. Oesterling JE (1994) Endocrine therapies for symptomatic benign prostatic hyperplasia. Urology 43(2 Suppl):7–16
23. Alonzi R, Padhani AR, Taylor NJ, Collins DJ, D’Arcy JA, Stirling JJ, Saunders MI, Hoskin PJ (2011) Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: an in vivo human study using susceptibility and relaxivity dynamic MRI. Int J Radiat Oncol Biol Phys 80(3):721–727
24. Kravchick S, Cytron S, Mamonov A, Peled R, Linov L (2009) Effect of short-term dutasteride therapy on prostate vascularity in patients with benign prostatic hyperplasia: a pilot study. Urology 73(6):1274–1278
25. Godoy A, Montecinos VP, Gray DR, Sotomayor P, Yau JM, Vethanayagam RR, Singh S, Mohler JL, Smith GJ (2011) Androgen deprivation induces rapid involution and recovery of human prostate vasculature. Am J Physiol Endocrinol Metab 300(2):E263–E275
26. Jaffe EA, Nachman RL, Becker CG, Minick CR (1973) Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 52(11):2745–2756. doi:10.1172/JCI107470
27. Nachman RL, Jaffe EA (2004) Endothelial cell culture: beginnings of modern vascular biology. J Clin Invest 114(8):1037–1040. doi:10.1172/JCI23284
28. Sotomayor P, Godoy A, Smith GJ, Huss WJ (2009) Oct4A is expressed by a subpopulation of prostate neuroendocrine cells. Prostate 69(4):401–410
29. Cano P, Godoy A, Escamilla R, Dhir R, Onate SA (2007) Stromal–epithelial cell interactions and androgen receptor-coregulator recruitment is altered in the tissue microenvironment of prostate cancer. Cancer Res 67(2):511–519
30. Shafi AA, Putluri V, Arnold JM, Tsouko E, Maity S, Roberts JM, Coarfa C, Frigo DE, Putluri N, Sreekumar A, Weigel NL (2015) Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells. Oncotarget 6(31):31997–32012. doi:10.18632/oncotarget.5585
31. von der Ahe D, Janich S, Scheidereit C, Renkawitz R, Schutz G, Beato M (1985) Glucocorticoid and progesterone receptors bind to the same sites in two hormonally regulated promoters. Nature 313(6004):706–709
32. Hsing AW, Reichardt JK, Stanczyk FZ (2002) Hormones and prostate cancer: current perspectives and future directions. Prostate 52(3):213–235
33. Bishop-Bailey D, Walsh DT, Warner TD (2004) Expression and activation of the farnesoid X receptor in the vasculature. Proc Natl Acad Sci USA 101(10):3668–3673
34. He F, Li J, Mu Y, Kuruba R, Ma Z, Wilson A, Alber S, Jiang Y, Stevens T, Watkins S, Pitt B, Xie W, Li S (2006) Downregulation of endothelin-1 by farnesoid X receptor in vascular endothelial cells. Circ Res 98(2):192–199
35. Wang S, Lai K, Moy FJ, Bhat A, Hartman HB, Evans MJ (2006) The nuclear hormone receptor farnesoid X receptor (FXR) is activated by androsterone. Endocrinology 147(9):4025–4033. doi:10.1210/en.2005-1485
36. Huber RM, Murphy K, Miao B, Link JR, Cunningham MR, Rupar MJ, Gunyuzlu PL, Haws TF, Kassam A, Powell F, Hollis GF, Young PR, Mukherjee R, Burn TC (2002) Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters. Gene 290(1–2):35–43
37. Lobo RA, Speroff L (1994) International consensus conference on postmenopausal hormone therapy and the cardiovascular system. Fertil Steril 61(4):592–595
38. Milewich L, Kaimal V, Johnson AR (1987) Steroid 5 alpha-reductase activity in endothelial cells from human umbilical cord vessels. J Steroid Biochem 26(5):561–567
39. Mukherjee TK, Dinh H, Chaudhuri G, Nathan L (2002) Testosterone attenuates expression of vascular cell adhesion molecule-1 by conversion to estradiol by aromatase in endothelial cells: implications in atherosclerosis. Proc Natl Acad Sci USA 99(6):4055–4060
40. Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1(1):34–45
41. Tan J, Sharief Y, Hamil KG, Gregory CW, Zang DY, Sar M, Gumerlock PH, deVere White RW, Pretlow TG, Harris SE, Wilson EM, Mohler JL, French FS (1997) Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 11(4):450–459
42. Sieveking DP, Lim P, Chow RW, Dunn LL, Bao S, McGrath KC, Heather AK, Handelsman DJ, Celermajer DS, Ng MK (2010) A sex-specific role for androgens in angiogenesis. J Exp Med 207(2):345–352
43. Antonarakis ES, Luo J (2015) Prostate cancer: AR splice variant dimerization—clinical implications. Nat Rev Urol 12(8):431–433. doi:10.1038/nrurol.2015.184
44. Leibrand CR, Price DK, Figg WD (2016) Androgen receptor splice variant 7 (AR-V7) and drug efficacy in castration-resistant prostate cancer: biomarker for treatment selection exclusion or inclusion? Cancer Biol Ther. doi:10.1080/15384047.2016.1156274
45. Yoshida S, Aihara K, Ikeda Y, Sumitomo-Ueda Y, Uemoto R, Ishikawa K, Ise T, Yagi S, Iwase T, Mouri Y, Sakari M, Matsumoto T, Takeyama K, Akaike M, Matsumoto M, Sata M, Walsh K, Kato S (2013) Androgen receptor promotes sex-independent angiogenesis in response to ischemia and is required for activation of vascular endothelial growth factor receptor signaling. Circulation 128(1):60–71. doi:10.1161/CIRCULATIONAHA.113.001533
46. Montecinos VP, Godoy A, Hinklin J, Vethanayagam RR, Smith GJ (2012) Primary xenografts of human prostate tissue as a model to study angiogenesis induced by reactive stroma. PLoS One 7(1):e29623. doi:10.1371/journal.pone.0029623
47. Montecinos VP, Morales CH, Fischer TH, Burns S, San Francisco IF, Godoy AS, Smith GJ (2015) Selective targeting of bioengineered platelets to prostate cancer vasculature: new paradigm for therapeutic modalities. J Cell Mol Med 19(7):1530–1537. doi:10.1111/jcmm.12515
48. Tanner MJ, Welliver RC Jr, Chen M, Shtutman M, Godoy A, Smith G, Mian BM, Buttyan R (2011) Effects of androgen receptor and androgen on gene expression in prostate stromal fibroblasts and paracrine signaling to prostate cancer cells. PLoS One 6(1):e16027. doi:10.1371/journal.pone.0016027
49. Balk SP, Knudsen KE (2008) AR, the cell cycle, and prostate cancer. Nucl Recept Signal 6:e001
50. Cai J, Hong Y, Weng C, Tan C, Imperato-McGinley J, Zhu YS (2011) Androgen stimulates endothelial cell proliferation via an androgen receptor/VEGF/cyclin A-mediated mechanism. Am J Physiol Heart Circ Physiol 300(4):H1210–H1221. doi:10.1152/ajpheart.01210.2010
51. Das A, Yaqoob U, Mehta D, Shah VH (2009) FXR promotes endothelial cell motility through coordinated regulation of FAK and MMP-9. Arterioscler Thromb Vasc Biol 29(4):562–570